PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

To study the radioactive uptake of [68Ga]P137 in the lesion sites of PCa patients and evaluate the ability of [68Ga]P137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Cancer Hospital
• Treatments: Choline

Criteria

Inclusion Criteria:

• Men over 18 years of age need to undergo [68Ga]P137 PET/CT examination for suspected prostate cancer.

• The patients can fully understand and voluntarily participate in this experiment, and sign the informed consent.

Exclusion Criteria:

• Significant hepatic or renal dysfunction;

• Patients with malignant tumors other than prostate cancer within 2 years;

• Ready to pregnant;

• The patient can not tolerate all clinical tests.